INDOCO REMEDIES LTD. - 532612 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Indoco Remedies Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here INDOCO REMEDIES LTD. - 532612 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Details of voting results in Compliance with Regulation 44 of the LODR in relation to 73rd Annual General Meeting of the Company held on 24.09.2020 Indoco Remedies surges 28% in 4 days post USFDA nod for Apixaban tablets
As per IMS MAT June'20 data, the US market size of Apixaban tablets is $11,037 million. Indoco Remedies soars 19% on US FDA approval for Apixaban tablets
Apixaban is an anticoagulant, or blood thinner, used for patients with health problems caused by a blood clot INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco receives USFDA approval for Apixaban Tablets INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Credit Rating
DISCLOSURE UNDER REG 30 OF LODR REG.2015 CREDIT RATING BY ICRA INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice published in newspapers informing 73rd AGM of the Company. INDOCO REMEDIES LTD. - 532612 - Reg. 34 (1) Annual Report
NOTICE OF 73RD AGM & ANNUAL REPORT 2019-20
Buy Indoco Remedies; target of Rs 330: ICICI Direct
ICICI Direct is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 330 in its research report dated August 12, 2020. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Financial Results for the Quarter ended 30th June, 2020